OPDIVO Qvantig™ (nivolumab + hyaluronidase-nvhy) is approved as a subcutaneous injection 

Dosing schedules

 Kidney icon

Find dosing information to get patients with advanced renal cell carcinoma started on therapy

1L Intermediate- or Poor-Risk Advanced RCC1,2

INDICATIONS

INTRAVENOUS USE OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma (RCC). View OPDIVO IV dosing schedule >

SUBCUTANEOUS USE OPDIVO Qvantig, as monotherapy, is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma (RCC) following treatment with intravenous nivolumab and ipilimumab combination therapy.

Limitations of Use: OPDIVO Qvantig is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma.

OPDIVO Qvantig Maintenance Therapy after IV OPDIVO + YERVOY combination therapy
DOSING & SCHEDULE DURATION
OPDIVO + YERVOY Induction phase* (weight-based)
3 mg/kg of OPDIVO IV infusion over 30 minutes followed on the same day by 1 mg/kg of YERVOY IV infusion over 30 minutes q3w for 4 doses of combination therapy
OPDIVO Qvantig Maintenance phase

600 mg nivolumab and 10,000 units hyaluronidase subcutaneous injection over 3-5 minutes q2w

OR

1,200 mg nivolumab and 20,000 units hyaluronidase subcutaneous injection over 3-5 minutes q4w

Until disease progression or unacceptable toxicity

After completing 4 doses of the combination therapy with ipilimumab in the induction phase, administer OPDIVO Qvantig as a single agent.

No premedications are required.

*When OPDIVO is administered in combination with YERVOY, if OPDIVO is withheld or discontinued, YERVOY should also be withheld or discontinued.1
Interrupt or slow the rate of infusion in patients with mild or moderate infusion-related reactions. Discontinue OPDIVO or OPDIVO + YERVOY in patients with severe or life-threatening infusion-related reactions.1

Review the U.S. Full Prescribing Information for OPDIVO Qvantig, OPDIVO, and YERVOY.

1L Advanced RCC1,2

INDICATIONS

INTRAVENOUS USE OPDIVO, in combination with cabozantinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). View OPDIVO IV dosing schedule >

SUBCUTANEOUS USE OPDIVO Qvantig, in combination with cabozantinib, is indicated for the first-line treatment of adult patients with advanced RCC.

OPDIVO Qvantig + Cabozantinib
DOSING & SCHEDULE DURATION
OPDIVO Qvantig

600 mg nivolumab and 10,000 units hyaluronidase subcutaneous injection over 3-5 minutes q2w

OR

1,200 mg nivolumab and 20,000 units hyaluronidase subcutaneous injection over 3-5 minutes q4w

Until disease progression, unacceptable toxicity, or up to 2 years
Cabozantinib
Administer OPDIVO Qvantig in combination with 40 mg cabozantinib orally once daily without food

Until disease progression or unacceptable toxicity

No premedications are required.

Review the U.S. Full Prescribing Information for OPDIVO Qvantig and cabozantinib.

Advanced RCC who have received prior antiangiogenic therapy1,2

INDICATIONS

INTRAVENOUS USE OPDIVO, as a single agent, is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. View OPDIVO IV dosing schedule >

SUBCUTANEOUS USE OPDIVO Qvantig, as monotherapy, is indicated for the treatment of adult patients with advanced RCC who have received prior anti-angiogenic therapy.

OPDIVO Qvantig Monotherapy
DOSING & SCHEDULE DURATION

600 mg nivolumab and 10,000 units hyaluronidase subcutaneous injection over 3-5 minutes q2w

OR

1,200 mg nivolumab and 20,000 units hyaluronidase subcutaneous injection over 3-5 minutes q4w

Until disease progression or unacceptable toxicity

No premedications are required.

Review the U.S. Full Prescribing Information for OPDIVO Qvantig.

IV=intravenous; q2w=every 2 weeks; q3w=every 3 weeks; q4w=every 4 weeks.

IMARS icon
Treatment Modifications

See recommended dosing modifications for immune-mediated adverse reactions with OPDIVO, YERVOY, or OPDIVO Qvantig.

Clipboard with checklist icon
Preparation and Administration

Find instructions for preparation, administration, and storage for both OPDIVO infusions and OPDIVO Qvantig subcutaneous injections.

OPDIVO® (nivolumab) dosing guide icon
Dosing Guide

A guide to dosing intravenous OPDIVO and subcutaneous injection OPDIVO Qvantig.
 

References:

  1. OPDIVO [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
  2. OPDIVO Qvantig [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.


1506-US-2400780  04/25